Epirubicin Market Size - Global Analysis Report 2022 - 2028

report image

Epirubicin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Dosage (10mg/Vial, 50mg/Vial, 100mg/Vial and 200mg/Vial), Application (Breast cancer, Liver Cancer, Bladder Cancer, and Others), and Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies)

Publication Month: Jul 2022 | Report Code: TIPRE00008627 | No. of Pages: 163 | Category: Pharmaceuticals | Status: Published

The epirubicin market is projected to reach US$ 243.99 million by 2028 from US$ 191.66 million in 2021; it is expected to register a CAGR of 3.60% from 2022 to 2028.

Epirubicin is an anthracycline medicine with the first clinical trial published in 1980. The drug was designed to be favored over doxorubicin because of better efficacity and quality. It is used for chemotherapy purposes for the treatment of various cancers. The drug is prescribed alone or in combination for the primary use against breast cancer, ovarian cancer, liver cancer, bladder cancer, and others. The product works by slowing or stopping the growth of cancer cells in the body. Combination therapies include fluorouracil, epirubicin hydrochloride, and cyclophosphamide (FEC), in which the product is given along with fluorouracil and cyclophosphamide. Adjuvant therapy of epirubicin seems to be less toxic compared to monotherapy. It is marketed by Pfizer under the trade name Ellence in the US and Pharmorubicin or Epirubicin Ebewe elsewhere. In August 2007, the product lost its patent and became generic. The product shows the limited scope in cancer treatment due to its side effects. The common side effect was the heart, bone marrow, and blood.

Epirubicin (EPI) was successfully incorporated into a solid-liquid nanoparticle formulation to produce a stable inhalable nebulized suspension for treating lung cancer.

Strategic Insights

Report Coverage - Epirubicin Market
Report CoverageDetails
Market Size Value inUS$ 191.66 Million in 2021
Market Size Value byUS$ 243.99 Million by 2028
Growth rateCAGR of 3.60% from 2022 to 2028
Forecast Period2022-2028
Base Year2021
No. of Pages163
No. of Tables88
No. of Charts & Figures75
Historical data availableYes
Segments coveredDosage, Application, and Distribution Channel
Regional scopeNorth America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country scopeUS, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Free Sample Copy Available

The epirubicin market  is segmented based on dosage, application, distribution channel, and geography. By geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. This report offers insights and in-depth analysis of the market, emphasizing parameters, such as market trends and market dynamics and the competitive analysis of the globally leading market players.

Lucrative Regions for Epirubicin Market

Lucrative Regions for Epirubicin Market

Get more information on this report :

Market Insights

Rising Prevalence of Cancer

Epirubicin is an anticancer drug that falls under the category of anthracyclines and is used to treat breast cancer, stomach cancers, etc. It reduces the risk of relapse by attacking any remaining tumor cells after surgery or radiation therapy has removed most of them.

According to the American Cancer Society, the global burden of cancer is estimated to have risen to 19.3 thousand new cases in 2021 and 10.0 thousand deaths in 2020. As per the National Cancer Institute (US), an increase in the incidence and prevalence of cancer has a significant impact on society globally. According to stats by the institute, in the US, nearly 1.8 thousand people were diagnosed with cancer, and about 606,520 people developed the disease in 2020. According to the International Agency for Research on Cancer, in 2020, the incidence of breast cancer was 2,261,419, accounting for approximately 11.7% of the total cancer cases globally. Moreover, the disease accounted for 684,996 mortalities in 2020. Thus, the high incidence rate associated with cancer is expected to impact market growth significantly. According to the Centers for Disease Control and Prevention (CDC), each year in the US, about 24,500 men and 10,000 women get liver cancer, and about 18,600 men and 9,000 women die from the disease. The percentage of Americans who get liver cancer has been rising for several decades. Liver cancer is more common in other parts of the world than in the US. Hence, the rising prevalence of cancer cases is driving the epirubicin market.

The healthcare industry in the Middle East & Africa region is still developing; hence, they faced the biggest challenge due to the COVID-19 pandemic. Health authorities were worried that attempting to fight COVID-19 would indirectly contribute to an increase in deaths of ill patients, including cancer patients. The death pool of ill patients in low-cost regions was expected to increase because healthcare professionals limited their patient appointments as many hospitals had limited resources and staff.

However, the launch of COVID vaccination programs in the year 2021, in several countries controlled the situation. These efforts to control the spread will ultimately recover and restore the situations post-pandemic.

Examples of development that have promoted the growth of the epirubicin market are listed below:

  • In April 2018, Hikma Pharmaceuticals PLC (Hikma, Group) announced that its wholly-owned US subsidiary West-Ward Pharmaceuticals Corp. (West-Ward), had launched Epirubicin Hydrochloride Injection, USP in 50mg/25mL and 200mg/100mL vials, the generic equivalent to Ellence. West-Ward’s Epirubicin Hydrochloride Injection, USP is a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.

Epirubicin Market - Application Insights

Based on application, the epirubicin market is segmented into breast cancer, liver cancer, bladder cancer, and other cancer. The breast cancer segment held the largest share of the market in 2021. The breast cancer segment is anticipated to register the highest CAGR in the market during the forecast period and the same segment is anticipated to register the highest CAGR during the forecast period. In the 1970s, epirubicin was launched as a drug to treat metastatic breast cancer, and at present, it is among the most active single agents treating breast cancer. Medicine can be used at an early stage of breast cancer to reduce the chances of breast cancer reoccurrence. It is widely used as adjuvant therapy for those who have had surgery and lymph nodes. Hence, in most cases, the medicine is usually prescribed with other medicines. In some instances, it can be used as a substitute for doxorubicin (Adriamycin) as it may cause less heart damage than doxorubicin. The medicine is injected into a vein and is often given once every three weeks or twice every 28 days for 6 cycles. The drug is made available in the market by Pfizer, Inc., and Sandoz (a Novartis AG Division), among others. There has been constant development in cancer therapeutics; hence, various companies are launching products in the market. For instance, in April 2018, Hikma Pharmaceuticals PLC launched Epirubicin Hydrochloride Injection, USP, in variants such as 50mg/25mL and 200mg/100mL vials. The product is the generic version and is equivalent to Ellence. Thus, product availability and product launches in the market are likely to enhance the market's growth during the forecast period.

Epirubicin Market, by Application – 2021 and 2028

Epirubicin Market, by Application – 2021 and 2028

Get more information on this report :

Epirubicin Market - Dosage Insights

Based on dosage, the global epirubicin market is segmented into 10mg/vial, 50mg/vial, 100mg/vial, and 200mg/vial. The 50mg/vial segment held the largest share of the market in 2021; however, the 100mg/vial segment is anticipated to register the highest CAGR during the forecast period. Epirubicin 50 mg injection is an anticancer agent which is used as an adjuvant drug to treat breast cancer. It is vesicant and should be injected into veins under the supervision of qualified physicians. The effect of 10 mg epirubicin lasts for an average of 3 to 4 days. Market players operating in the epirubicin market are offering epirubicin in different dosages. For instance, Pfizer is offering epirubicin hydrochloride in 10 mg and 50 mg dosages.

Epirubicin Market - Distribution Channel Insights

Based on distribution channel, the global epirubicin market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share of the market in 2021. The same segment is anticipated to register the highest CAGR of 4.0% in the market during the forecast period. Hospital pharmacies are an integral aspect of patient care at a healthcare facility. Hospital pharmacy is the field that works to consistently uphold and enhance patient pharmaceutical care and medication management to the highest standards possible in a hospital setting. The hospital pharmacy is one of the primary areas in hospitals where pharmaceuticals are purchased, stored, compounded, dispensed, manufactured, tested, packaged, and distributed. Controlling the usage of pharmaceuticals in hospitals and other medical facilities is the main responsibility of hospital pharmacies. The selection, prescription, procurement, delivery, administration, and review of pharmaceuticals are among the objectives that aim to improve patient outcomes.

Epirubicin Market – by Region

By geography, the epirubicin market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).  

Epirubicin Market - Company Profiles

The epirubicin market majorly consists of players such as Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Salius Pharma Pvt Ltd; Areva Pharmaceuticals; Mylan N. V.; Hikma Pharmaceuticals PLC; Fresenius Kabi AG; and Miracalus Pharma Pvt. Ltd.

Frequently Asked Questions

Epirubicin HCl is a class of drugs termed anthracyclines and is primarily used to treat breast cancers after surgical resection. Anthracyclines are an antibiotic isolated from the gram-positive bacteria Streptomyces. They are commonly used as chemotherapy agents and exert their antineoplastic effects by targeting the replication of DNA. Epirubicin HCl is often preferred over anthracycline doxorubicin as it has been shown to have fewer side effects. Epirubicin HCl became FDA-approved as adjuvant therapy for treating axillary node-positive breast cancers following resection under the trade name Ellence in 1999. It is currently manufactured through large-scale semi-synthetic methods using daunorubicin as starting material for its preparation.
Factors such as rising prevalence of cancer and increasing awareness regarding cancer are propelling the market growth.
The elevated risk of adverse effects due to epirubicin is hampering the market's growth.
The epirubicin market majorly consists of the players such as Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Salius Pharma Pvt Ltd; Areva Pharamceuticals; Mylan N. V.; Hikma Pharmaceuticals PLC; Fresenius Kabi AG; and Miracalus Pharma Pvt. Ltd.
Based on dosage, the global epirubicin market is segmented into 10mg/Vial, 50mg/Vial, 100mg/Vial, and 200mg/Vial. The 50mg/Vial segment held the largest share of the market in 2021, however, 100mg/Vial segment is anticipated to register the highest CAGR in the market during the forecast period.
The global epirubicin market on region, is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and the South & Central America. North America held the largest market share for epirubicin in 2021. The United States held the largest market in North America for epirubicin, and the market is expected to grow due to rising prevalence of cancer and rising emphasis on improving treatment outcomes are projected to accelerate the growth of the epirubicin market.

The List of Companies - Epirubicin Market

  1. Pfizer, Inc.
  2. Teva Pharmaceutical Industries Ltd.
  3. Salius Pharma Pvt Ltd
  4. Areva Pharmaceuticals Mylan N. V.
  5. Hikma Pharmaceuticals PLC
  6. Fresenius Kabi AG
  7. Miracalus Pharma Pvt. Ltd.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the epirubicin market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global epirubicin market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TIPRE00008627
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market


Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
Pricing
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount